BioXcel Therapeutics Inc.：Bxcl501在治疗阿片类药物戒断症状中展现出临床获益与良好耐受性

美股速递03-05

BioXcel Therapeutics Inc.公布的最新临床数据显示，其研究性药物Bxcl501在治疗阿片类药物戒断症状方面表现出显著的临床益处和良好的耐受性特征。该结果突显了该疗法在应对这一严峻公共卫生挑战方面的潜力。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1115086186?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-05 20:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115086186","market":"us","top_or_hot":-1,"title":"BioXcel Therapeutics Inc.：Bxcl501在治疗阿片类药物戒断症状中展现出临床获益与良好耐受性","media":"美股速递","content":"<p>BioXcel Therapeutics Inc.公布的最新临床数据显示，其研究性药物Bxcl501在治疗阿片类药物戒断症状方面表现出显著的临床益处和良好的耐受性特征。该结果突显了该疗法在应对这一严峻公共卫生挑战方面的潜力。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioXcel Therapeutics Inc.：Bxcl501在治疗阿片类药物戒断症状中展现出临床获益与良好耐受性</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioXcel Therapeutics Inc.：Bxcl501在治疗阿片类药物戒断症状中展现出临床获益与良好耐受性\n</h2>\n\n<h4 class=\"meta\">\n\n2026-03-05 20:10 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioXcel Therapeutics Inc.公布的最新临床数据显示，其研究性药物Bxcl501在治疗阿片类药物戒断症状方面表现出显著的临床益处和良好的耐受性特征。该结果突显了该疗法在应对这一严峻公共卫生挑战方面的潜力。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1115086186","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115086186","pubTimestamp":1772712603,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BioXcel Therapeutics Inc.公布的最新临床数据显示，其研究性药物Bxcl501在治疗阿片类药物戒断症状方面表现出显著的临床益处和良好的耐受性特征。该结果突显了该疗法在应对这一严峻公共卫生挑战方面的潜力。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","BTAI":"Bioxcel Therapeutics Inc."},"translate_title":"BioXcel Therapeutics Inc.: Bxcl501 Exhibits Clinical Benefit and Good Tolerability in the Treatment of Opioid Withdrawal Symptoms","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BTAI":1},"content_text":"BioXcel Therapeutics Inc.公布的最新临床数据显示，其研究性药物Bxcl501在治疗阿片类药物戒断症状方面表现出显著的临床益处和良好的耐受性特征。该结果突显了该疗法在应对这一严峻公共卫生挑战方面的潜力。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115086186","isCrawlerRequest":true}